Solanki Avani, Mohanty Purvi, Shukla Pallavi, Rao Anita, Ghosh Kanjaksha, Vundinti Babu Rao
Department of Cytogenetics, National Institute of Immunohaematology (ICMR), Mumbai, Maharashtra, India.
PLoS One. 2016 Jan 22;11(1):e0147016. doi: 10.1371/journal.pone.0147016. eCollection 2016.
Fanconi anemia (FA), a rare heterogeneous genetic disorder, is known to be associated with 19 genes and a spectrum of clinical features. We studied FANCA molecular changes in 34 unrelated and 2 siblings of Indian patients with FA and have identified 26 different molecular changes of FANCA gene, of which 8 were novel mutations (a small deletion c.2500delC, 4 non-sense mutations c.2182C>T, c.2630C>G, c.3677C>G, c.3189G>A; and 3 missense mutations; c.1273G>C, c.3679 G>C, and c.3992 T>C). Among these only 16 patients could be assigned FA-A complementation group, because we could not confirm single exon deletions detected by MLPA or cDNA amplification by secondary confirmation method and due to presence of heterozygous non-pathogenic variations or heterozygous pathogenic mutations. An effective molecular screening strategy should be developed for confirmation of these mutations and determining the breakpoints for single exon deletions.
范可尼贫血(FA)是一种罕见的遗传性异质性疾病,已知与19个基因及一系列临床特征相关。我们研究了34名无亲缘关系的印度FA患者以及2名患者同胞的FANCA分子变化,共鉴定出FANCA基因的26种不同分子变化,其中8种为新突变(一个小缺失c.2500delC、4个无义突变c.2182C>T、c.2630C>G、c.3677C>G、c.3189G>A;以及3个错义突变c.1273G>C、c.3679G>C和c.3992T>C)。其中只有16名患者可被归为FA-A互补组,原因是我们无法通过二次确认方法证实MLPA检测到的单外显子缺失或cDNA扩增结果,以及存在杂合的非致病性变异或杂合的致病性突变。应制定有效的分子筛查策略来确认这些突变并确定单外显子缺失的断点。